While the life sciences and health care industry is witnessing a rise of environmental and societal impact, how focused are investors in this regard? At the same time, the role of companies in tackling the pandemic is more important than ever. While technological innovation is constantly disrupting the pharma landscape, how will it reshape manufacturing and supply chains for uninterrupted operations in the new normal? The industry has also been embracing patient-centered approaches in its strive to improve consumer empowerment. But, does patient centricity make strategic sense? Deloitte leaders, along with industry peers, unpacked many of these critical questions at the FT Global Pharmaceutical & Biotechnology Conference 2021, which brought together the biggest life sciences and health care leaders from across the globe virtually to discuss. The leaders navigated the route to deliver better health care outcomes in an uncertain world.
Innovating and collaborating: Assess the legacy of COVID-19 for healthcare and life sciences and the potential impact on how products are developed in the future
Investing and expanding: Explore the pharma biotech investment landscape and identify opportunities for growth around the world
Engaging and empowering: Gain global insights on market access and the future of healthcare from different stakeholders including pharma, payers, patients and regulators
DIALOGUE: WHAT DOES THE RISE OF ESG MEAN FOR THE HEALTHCARE SECTOR?
In this session, the industry and government leaders discussed how can healthcare sector companies build on their role in tackling the pandemic to attract socially responsible investors to focus on ESG.
Panelists:
Daniella Foster, Global VP and Head of Public Affairs, Science and Sustainability, Consumer Health, Bayer
Nazneen Rahman, Founder and CEO, YewMaker
Moderated by - James Gregson, Life Sciences & Healthcare industry leader, Deloitte UK
In this session, the panel members discussed about the shift in balance of power between pharma, payers, patients and other stakeholders shift in the next few years. They also discussed on how new drugs should be brought to market.
Panelists:
Carole Longson, Life Sciences Advisor, Centre for Health Technology Evaluation, NICE
Margo Warren, Head of Policy, Access to Medicines Foundation
Sanjay Gupta, Vice President and Head of Global Real-World Experience (RWE) and US Health Economics & Outcomes Research (HEOR), Oncology Business Group, Eisai
Moderated by - Hanno Ronte, Life Sciences & Healthcare industry leader, Deloitte Monitor
This session discussed about how business models are affected by making patient centricity more of a priority and the leaders and industry experts also decoded the meaning for the balance of power between pharma and the patient.
In this session, leaders discussed the lessons pandemic taught us about how to support vaccine development and access in an emergency. They also mapped the commercial landscape for vaccines evolving and what can we expect to see in terms of innovation.
Panelists:
Judy Stewart, Senior Vice President, Head of US Vaccines, GlaxoSmithKline
In this session, the panelists discussed about the vast scope for innovation with much investment going into the development of off-the-shelf allogeneic therapies. They also looked at the market trends for cell and gene therapies and prospects for allogeneic therapies for conditions other than cancer.
Panelists:
Matthew Durdy, CEO, Cell and Gene Therapy, Catapult
Dick Sundh, Vice President, Head of Australia, Canada and Europe, Kite, a Gilead Company
Jo Brewer, SVP Allogeneic Research, Adaptimmune
Richard Scott, Chief Medical Officer, Genomics England
Moderated by -Hussain Mooraj, Next Gen Therapy Practice Lead, Principal, Deloitte Consulting LLP
*Registration required to access conference recordings. Complimentary registration is available for senior executives in the life sciences and health care industry only and is subject to final approval by the Financial Times Live.
